Literature DB >> 23694754

ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia.

Masatoshi Takagi1, Masaki Sato, Jinhua Piao, Satoshi Miyamoto, Takeshi Isoda, Masanobu Kitagawa, Hiroaki Honda, Shuki Mizutani.   

Abstract

Chronic myelogenous leukemia (CML) begins with an indolent chronic phase, and subsequently progresses to an accelerated or blastic phase. Although several genes are known to be involved in the progression to blastic phase, molecular mechanisms for the evolution toward blast crisis have not been fully identified. Oncogenic stimuli enforce cell proliferation, which requires DNA replication. Unscheduled DNA replication enforced by oncogenic stimuli leads to double strand breaks on DNA. We found the DNA damage-response pathway is activated in bone marrow of chronic-phase CML patients possibly due to an enforced proliferation signal by BCR-ABL expression. Since ataxia telangiectasia mutated (ATM) is a central player of the DNA damage-response pathway, we studied whether loss of this pathway accelerates blast crisis. We crossed Atm-knockout mice with BCR-ABL transgenic mice to test this hypothesis. Interestingly, the loss of one of the Atm alleles was shown to be enough for the acceleration of the blast crisis, which is supported by the finding of increased genomic instability as assayed by breakage-fusion-bridge (BFB) cycle formation. In light of these findings, the DNA damage-response pathway plays a vital role for determination of susceptibility to blast crisis in CML.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23694754     DOI: 10.1016/j.dnarep.2013.04.022

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  12 in total

Review 1.  DNA damage response and hematological malignancy.

Authors:  Masatoshi Takagi
Journal:  Int J Hematol       Date:  2017-04-03       Impact factor: 2.490

2.  Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Authors:  Tri Nguyen; Elisa Hawkins; Akhil Kolluri; Maciej Kmieciak; Haeseong Park; Hui Lin; Steven Grant
Journal:  Leuk Res       Date:  2014-11-11       Impact factor: 3.156

3.  ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Xuezhen Luo; Chengcheng Ning; Yinhua Yu; Youji Feng; Chao Gu; Xiaojun Chen
Journal:  Tumour Biol       Date:  2015-01-22

4.  Developmental and cancer-associated plasticity of DNA replication preferentially targets GC-poor, lowly expressed and late-replicating regions.

Authors:  Xia Wu; Hadi Kabalane; Malik Kahli; Nataliya Petryk; Bastien Laperrousaz; Yan Jaszczyszyn; Guenola Drillon; Frank-Emmanuel Nicolini; Gaëlle Perot; Aude Robert; Cédric Fund; Frédéric Chibon; Ruohong Xia; Joëlle Wiels; Françoise Argoul; Véronique Maguer-Satta; Alain Arneodo; Benjamin Audit; Olivier Hyrien
Journal:  Nucleic Acids Res       Date:  2018-11-02       Impact factor: 16.971

5.  Expression of minichromosome maintenance 8 in chronic myelogenous leukemia.

Authors:  Lili Cai; Kai Zhao; Xuejie Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 6.  The cell cycle checkpoint inhibitors in the treatment of leukemias.

Authors:  A Ghelli Luserna di Rora'; I Iacobucci; G Martinelli
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388

Review 7.  Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Authors:  Jan Stetka; Jan Gursky; Julie Liñan Velasquez; Renata Mojzikova; Pavla Vyhlidalova; Lucia Vrablova; Jiri Bartek; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

8.  Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Authors:  Satoshi Inoue; Wanda Y Li; Alan Tseng; Isabel Beerman; Andrew J Elia; Sean C Bendall; François Lemonnier; Ken J Kron; David W Cescon; Zhenyue Hao; Evan F Lind; Naoya Takayama; Aline C Planello; Shu Yi Shen; Alan H Shih; Dana M Larsen; Qinxi Li; Bryan E Snow; Andrew Wakeham; Jillian Haight; Chiara Gorrini; Christian Bassi; Kelsie L Thu; Kiichi Murakami; Alisha R Elford; Takeshi Ueda; Kimberly Straley; Katharine E Yen; Gerry Melino; Luisa Cimmino; Iannis Aifantis; Ross L Levine; Daniel D De Carvalho; Mathieu Lupien; Derrick J Rossi; Garry P Nolan; Rob A Cairns; Tak W Mak
Journal:  Cancer Cell       Date:  2016-07-14       Impact factor: 31.743

Review 9.  DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.

Authors:  Elzbieta Pawlowska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

10.  Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.

Authors:  Mai Nanya; Masaki Sato; Kousuke Tanimoto; Minoru Tozuka; Shuki Mizutani; Masatoshi Takagi
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.